In response, pediatric research has gained momentum, mostnotably with the Prospective Trial to Assess the Angiotensin Receptor BlockerNeprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor forthe Medical Treatment of Pediatric HF (PANORAMA-HF) trial, which evaluatedsacubitril/valsartan in children with symptomatic HFrEF [6]. This evidence concerns the gene ACE and hydrops fetalis.